Prestige BioPharma invests its expertise and resources in the development of biosimilars and new first-in-class antibody therapeutics.
PBP’s current biosimilar portfolio includes:
PBP’s current first in class antibody therapeutics portfolio includes:
The first biosimilar of PBP, HD201 Trastuzumab, has been filed and accepted for review with the EMA, projecting market launch in 2021. Prestige BioPharma´s next products in line include a Bevacizumab biosimilar (HD204) in Phase III, an Adalimumab biosimilar (PBP1502) in Phase I, and an innovative anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in Phase I stages. Manufacturing facilities for global commercial supply are located in Osong, South Korea.
|HD201||Biosimilar, Trastuzumab (Herceptin)||Breast Cancer, Gastric Cancer|
|HD204||Biosimilar, Bevacizumab (Avastin)||Solid Tumors|
|PBP1502||Biosimilar, Adalimumab (Humira)||Arthritis|
|PBP1510||First In Class Antibody||Pancreatic Cancer|
|PBP1601||Biosimilar, Denosumab||Bone Loss, Osteoporosis|
|PBP1602||Biosimilar, Aflibercept||Macular Edema, Metastatic Colorectal Cancer, Retinopathy|
|PBP1603||Biosimilar, Eculizumab||Atypical Haemolytic Uremic Syndrome, Paraoxysmal Nocturnal Hemoglobinuria|
|PBP1701||Biosimilar, Ipilimumab||Metastatic Melanoma, Unresectable Melanoma|
|PBP1710||First In Class Antibody||Solid Tumors|
|PBP1801||Biosimilar, Pertuzumab (Perjeta)||Breast Cancer|